Singapore markets closed

SciSparc Ltd. (SPRC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6430-0.0866 (-11.87%)
At close: 04:00PM EDT
0.6251 -0.02 (-2.78%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7296
Open0.6925
Bid0.6229 x 100
Ask0.6678 x 100
Day's range0.6380 - 0.6925
52-week range0.6380 - 15.8574
Volume775,975
Avg. volume971,349
Market cap2.091M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)-14.4300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

    SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has signed a non-binding letter of intent (“LOI”) with an undisclosed biotechnology company to pursue the out-licensing of i

  • GlobeNewswire

    SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

    TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Na

  • GlobeNewswire

    SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

    TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office (“USPTO”) was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind"), a